Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2023-01-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于全资子公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (590 characters) from a company about its wholly-owned subsidiary receiving a High-Tech Enterprise Certificate, which grants tax benefits. It explains the certificate details and the impact on the company's tax rate and future earnings. There is no financial statement, no detailed report, no meeting materials, no voting results, no management changes, no earnings release, or other detailed financial or regulatory filings. The document is an announcement of a regulatory or corporate event related to tax status and benefits. It is not a full report or financial statement but a regulatory announcement informing the market of a material event. Given the short length and nature, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2023-01-09 Chinese
01.07：（2023-001）关于对全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of providing guarantees by the company to its wholly-owned subsidiary. It details the guarantee amount, the approval process by the board and shareholders, financial data of the subsidiary, and compliance with regulatory requirements. The document is relatively short (2646 characters) and focuses on a specific financing-related guarantee update rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes such as guarantees.
2023-01-06 Chinese
关于全资子公司获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (941 characters) from a company about its wholly-owned subsidiary receiving a government subsidy. It details the subsidy amount, accounting treatment, and expected impact on profits. There is no comprehensive financial report or detailed financial statements. The document is an announcement of a specific financial event (government subsidy) rather than a full financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about a financial event affecting the company, which fits best under Regulatory Filings (RNS).
2022-12-22 Chinese
独立董事对第八届董事会第四次（临时）会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting (the 8th Board of Directors, 4th (extraordinary) meeting). It discusses the use of idle raised funds to temporarily supplement working capital, referencing compliance with laws and company regulations. The document is short (799 characters) and focuses on board-level approval and opinions rather than full financial data or detailed financial statements. It is not a full annual or interim report, nor an earnings release. It is also not a regulatory filing or certification letter but a formal board/management related announcement about a board decision. Therefore, it fits best under Board/Management Information (MANG).
2022-11-14 Chinese
第八届董事会第四次（临时）会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions passed at the company's eighth board of directors' fourth (extraordinary) meeting. It details the meeting date, voting results, and decisions made, such as approval of exclusive license agreements and use of idle raised funds. It references other announcements for detailed disclosures. The content focuses on board meeting decisions and does not contain financial statements or detailed management reports. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report itself but a meeting resolution announcement, confirming the classification.
2022-11-14 Chinese
申万宏源证券承销保荐有限责任公司关于亿帆医药股份有限公司继续使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from a securities underwriting and sponsorship company regarding the continued use of idle raised funds by a pharmaceutical company for temporary working capital supplementation. It references regulatory guidelines and approvals related to the use of non-publicly issued stock funds from 2017. The document details the use and management of these funds, internal decision-making procedures, and the sponsor's verification opinion. It does not contain financial statements or comprehensive financial performance data but is a regulatory compliance and verification report related to fundraising use. The document length is 3544 characters, relatively short and focused on a specific regulatory compliance matter. This fits best under Audit Report / Information (AR), as it is a standalone audit/verification report on the use of raised funds, not a full annual or interim report, nor an announcement or presentation. Q4 2022
2022-11-14 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.